Aurora Spine Corporation to Attend Sixth Annual American Society of Pain & Neuroscience Conference
10 Juli 2024 - 1:15PM
Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV:
ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative
medical devices that improve spinal surgery outcomes, today
announced it will be participating in the Sixth Annual ASPN
Conference sponsored by The American Society of Pain Neuroscience
(ASPN) to be held July 11-14, 2024 at the Fontainebleau in Miami
Beach, Florida. Aurora will be located at Booth 121.
On July 12th, at 10:15 a.m., Aurora Spine will be hosting a
product theater debuting investigator-initiated real-world
prospective clinical research on SILO TFX and ZIP 51. Pankaj Mehta
MD, Steven Falowski MD, and Jason Pope MD will present a
comparative analysis from Aurora Spine’s Refine Study, the first
multi-center, multi-specialty, randomized control trial for
interlaminar fusion with neurosurgeons, ortho-spine surgeons, and
intervention pain physicians.
Trent Northcutt, President and Chief Executive Officer of Aurora
Spine, stated, “We are very excited to be participating in this
year’s ASPN Conference. We are proud to have an audience with
thought-leading physicians to learn about Aurora’s product
portfolio and clinical evidence.”
About Aurora Spine
Aurora Spine is focused on bringing new solutions to the spinal
implant and pain markets through a series of innovative, minimally
invasive, regenerative spinal implant technologies. Aurora Spine is
an emerging growth company focused on bringing new solutions to the
spinal implant and pain care markets through a series of screwless,
innovative, minimally invasive, regenerative spinal implant
technologies. Additional information can be accessed at
www.aurora-spine.com or www.aurorapaincare.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Forward-Looking Statements
This news release contains forward-looking information that
involves substantial known and unknown risks and uncertainties,
most of which are beyond the control of Aurora Spine, including,
without limitation, those listed under "Risk Factors" and
"Cautionary Statement Regarding Forward-Looking Information" in
Aurora Spine's final prospectus (collectively, "forward-looking
information"). Forward-looking information in this news release
includes information concerning the proposed use and success of the
company’s products in surgical procedures. Aurora Spine cautions
investors of Aurora Spine's securities about important factors that
could cause Aurora Spine's actual results to differ materially from
those projected in any forward-looking statements included in this
news release. Any statements that express, or involve discussions
as to, expectations, beliefs, plans, objectives, assumptions or
future events or performance are not historical facts and may be
forward-looking and may involve estimates, assumptions and
uncertainties which could cause actual results or outcomes to
differ unilaterally from those expressed in such forward-looking
statements. No assurance can be given that the expectations set out
herein will prove to be correct and, accordingly, prospective
investors should not place undue reliance on these forward-looking
statements. These statements speak only as of the date of this
press release and Aurora Spine does not assume any obligation to
update or revise them to reflect new events or circumstances.
Contact:
Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004
Chad Clouse
Chief Financial Officer
(760) 424-2004
www.aurora-spine.com
Aurora Spine (TSXV:ASG)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Aurora Spine (TSXV:ASG)
Historical Stock Chart
Von Okt 2023 bis Okt 2024